| DrugRepV_3540 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Shanghai/37T/2009(H1N1) |  | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3541 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Guizhou/54/1989(H3N2) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3542 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Shanghai/37T/2009(H1N1) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3543 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Guizhou/54/1989(H3N2) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_4297 | Piperazine | Antiparasitic products, Insectisides and Repellents | Parasitic infections (Ascariasis) | Chikungunya virus | DRDE-07 | NA | Plaque reduction assay | Decrease (81 %) | Approved, Vet approved | 28842264 |
| DrugRepV_4313 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Ebola virus | Sudan (Boneface strain) | NA | Plaque reduction assay | Decrease (50 %) | Approved | 9988190 |
| DrugRepV_4314 | Carbocyclic 3-deazaadenosine | NA | NA | Ebola virus | Sudan (Boneface strain) | NA | Plaque reduction assay | Decrease (50 %) | NA | 9988190 |
| DrugRepV_4315 | 9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine | NA | NA | Ebola virus | Sudan (Boneface strain) | NA | Plaque reduction assay | Decrease (50 %) | NA | 9988190 |
| DrugRepV_4316 | 9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine | NA | NA | Ebola virus | Sudan (Boneface strain) | NA | Plaque reduction assay | Decrease (50 %) | NA | 9988190 |
| DrugRepV_4519 | Alferon | NA | Condylomata acuminata | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 15200845 |
| DrugRepV_4520 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 15200845 |
| DrugRepV_4521 | Multiferon | Antineoplastic and Immunomodulating Agents | Hepatitis (viral, C) | Leukemia | Melanoma | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 15200845 |
| DrugRepV_5430 | Naltrexone | Nervous System | Alcohol dependence | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational, Vet approved | 31244822 |
| DrugRepV_5431 | Gallium nitrate | NA | NA | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 31244822 |
| DrugRepV_5432 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5433 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5434 | Naltrexone | Nervous System | Alcohol dependence | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational, Vet approved | 31244822 |
| DrugRepV_5435 | Gallium nitrate | NA | NA | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 31244822 |
| DrugRepV_5436 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5437 | Dextromethorphan | Respiratory System | Cough | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5438 | Naltrexone | Nervous System | Alcohol dependence | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational, Vet approved | 31244822 |
| DrugRepV_5439 | Gallium nitrate | NA | NA | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 31244822 |
| DrugRepV_5440 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5441 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_7221 | 2-(3-chlorophenoxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Plaque reduction assay | Decrease (60 %) | NA | 28068627 |
| DrugRepV_7222 | 2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Plaque reduction assay | Decrease (78 %) | NA | 28068627 |
| DrugRepV_7223 | 2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone | NA | NA | Yellow fever virus | NA | | Plaque reduction assay | Decrease (70 %) | NA | 28068627 |
| DrugRepV_7224 | 2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Plaque reduction assay | Decrease (40 %) | NA | 28068627 |
| DrugRepV_7225 | 2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Plaque reduction assay | Decrease (55 %) | NA | 28068627 |
| DrugRepV_7556 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7557 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7664 | Cetilistat | NA | Obesity | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 32473310 |
| DrugRepV_7665 | Diiodohydroxyquinoline | Genito Urinary System And Sex Hormones | Used in the treatment of amoebiasis. | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7666 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7667 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7701 | Pegasys | NA | Hepatitis C Virus | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 32532085 |
| DrugRepV_7702 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7703 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7704 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7705 | Immukin | NA | Chronic granulomatous disease and Osteopetrosis | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 32532085 |
| DrugRepV_7706 | 25-Hydroxycholesterol | NA | NA | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Experimental | 32532085 |
| DrugRepV_7707 | AM580 | NA | NA | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | NA | 32532085 |
| DrugRepV_7708 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7709 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Experimental | 32532085 |